BACKGROUND Oral cancer is the 8th most common cancer worldwide. Squamous cell carcinomas constitute 94% of all oral malignancies and are often preceded by leukoplakia. Despite many adjunctive techniques to monitor transformation of leukoplakia to oral squamous cell carcinoma (OSCC), the mortality rate is on the rise. Incidentally, patients diagnosed with oral potentially malignant disorders (OP...

Di(2-ethylhexyl)phthalate (DEHP), a peroxisome proliferator, has been listed by the International Agency for Research on Cancer (IARC) and by the National Toxicology Program as a possible or reasonably anticipated human carcinogen because it induces dose-related increases in liver tumors in both sexes of rats and mice. Recently, the suggestion has been advanced that DEHP should be considered un...

Poultry products are comparatively rich in cholesterol. WHO report indicates incidence of coronary heart disease and high dietary cholesterol level to be positively correlated. In such a situation, decreasing the cholesterol content in poultry products would be appropriate. Onion and garlic are ascribed with therapeutic effects such as hypocholesterolemia, hypolipidemia and immunosuppressant ac...

Melnick (1) recently suggested that because peroxisome proliferation is not established as an obligatory step in the carcinogenicity of peroxisome proliferators (PPs), the proposal that the peroxisome proliferator di(2-ethylhexyl)phthalate (DEHP) poses no carcinogenic risk to humans (2) due to species differences in peroxisome proliferation should be viewed as an unvalidated hypothesis (1). In ...

The changes occurring in hepatocytes of F-344 male rats during a 3-wk treatment with a hypolipidemic agent, 1-methyl-4-piperidyl-b/s[p-chlorophenoxy]acetate (Sail 42-348), have been evaluated by morphometric and biochemical methods. The twofold increase in liver weight resulted from a significant increase in hepatocyte cytoplasm as well as a moderate increase in the number of liver cells. The p...

The Abetalipoproteinemia and Related Disorders Foundation (ABLRDF) is a nonprofit organization founded in 2019 that comprised of patients with abetalipoproteinemia (ABL), familial hypobetalipoproteinemia (FHBL) related disorders as well their caregivers, researchers, medical professionals. real-world experience individuals within the ABLRDF provides closer examination unique struggles managing ...